237.85
-0.34 (-0.14%)
| Previous Close | 238.19 |
| Volume | 1,454,603 |
| Price / Earnings (Forward) | 19.83 |
| Price / Sales | 6.07 |
| Price / Book | 5.66 |
| 52 Weeks Range | |
| TTM Dividend Yield | 1.08% |
| Profit Margin | 26.15% |
| Operating Margin (TTM) | 33.00% |
| Diluted EPS (TTM) | 8.92 |
| Quarterly Revenue Growth (YOY) | 7.90% |
| Quarterly Earnings Growth (YOY) | 21.50% |
| Total Debt/Equity (MRQ) | 15.14% |
| Current Ratio (MRQ) | 3.41 |
| Operating Cash Flow (TTM) | 1.65 B |
| Levered Free Cash Flow (TTM) | 1.20 B |
| Return on Assets (TTM) | 14.01% |
| Return on Equity (TTM) | 25.81% |
News Mood
-
Don’t Lose Sleep Over GLP-1s: Why ResMed Stock Is a Bargain
06 Nov, 9:04PM
-
ResMed: 3 Key Takeaways for Long-Term Investors
02 Nov, 3:33AM
-
What Sent ResMed Stock Lower?
01 Nov, 7:23PM
AIStockmoo Score
| Value 30% | 1.5 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Priced high for its earnings growth. info | |
| The price implies earnings growth of 18.5% a year; the business can fund about 15.0% a year. info | |
| Cheaper than its usual valuation. info | |
| Low debt. Strong profitability. Ample short-term liquidity. Positive cash flow. info | |
| Earns well above its cost of capital. Returns on capital rising. info | |
| Timing 30% | 0.9 |
| From our AI technical analysis of the chart. info | NA |
| No clear trend over the past year. Somewhat below its 52-week high. info | |
| In an uptrend: the price is above its moving averages, and they are rising. It is close to them. A recent move above resistance has not been confirmed. info | |
| Candle Patterns info | NA |
| Above its medium-term trend line. info | |
| Sentiment 20% | 0.3 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Smart Money 20% | -2.5 |
| Several insiders net selling recently. Price is above where insiders sold. info | |
| Institutions net -4.56% of shares in their latest 13F filings: 414 holders increased, 481 decreased (quarter to 30 Sep 2026). info | |
| Market and sector conditions are neutral. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is high against its 52-week average. info | |
| Short-term momentum fading. info | |
| Price is between support and resistance. info | |
| Final Score | 0.22 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | ResMed Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| RMD | - | 1.08% | - | 5.66 |
| BDX | - | 2.20% | - | 2.41 |
| WST | - | 0.37% | - | 9.67 |
| BLCO | - | - | - | 1.17 |
| ALC | - | 0.49% | - | 1.64 |
| STVN | - | 0.30% | - | 2.39 |
Select this tab to load the latest available analysis.
|
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 0.78% |
| % Held by Institutions | 65.16% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BLOOMER AARON | - | 238.53 | -1,095 | -261,190 |
| DE WITTE JAN | - | 238.53 | -60 | -14,312 |
| FARRELL MICHAEL J. | - | 237.47 | -13,104 | -3,111,767 |
| FARRELL PETER C | - | 238.53 | -169 | -40,312 |
| GILL HARJIT | - | 238.53 | -36 | -8,587 |
| RIDER MICHAEL J | - | 238.53 | -1,944 | -463,702 |
| Aggregate Net Quantity | -16,408 | |||
| Aggregate Net Value ($) | -3,899,870 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 237.68 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RIDER MICHAEL J | Officer | 11 Nov 2026 | Disposed (-) | 1,944 | 238.53 | 463,702 |
| GILL HARJIT | Director | 11 Nov 2026 | Disposed (-) | 36 | 238.53 | 8,587 |
| DE WITTE JAN | Director | 11 Nov 2026 | Disposed (-) | 60 | 238.53 | 14,312 |
| FARRELL PETER C | Director | 11 Nov 2026 | Disposed (-) | 169 | 238.53 | 40,312 |
| BLOOMER AARON | Officer | 11 Nov 2026 | Disposed (-) | 1,095 | 238.53 | 261,190 |
| FARRELL MICHAEL J. | Officer | 11 Nov 2026 | Disposed (-) | 8,111 | 238.53 | 1,934,717 |
| FARRELL MICHAEL J. | Officer | 09 Nov 2026 | Automatic sell (-) | 4,993 | 235.74 | 1,177,050 |
| FARRELL MICHAEL J. | Officer | 09 Nov 2026 | Option execute | 4,993 | - | - |
Institutions
Institutional ownership: 80.42%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 414 | 4,315,361 |
| Decreased | 481 | 10,303,418 |
| New | 115 | 481,103 |
| Sold out | 117 | 920,995 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2026 | Yahoo Finance |
Don’t Lose Sleep Over GLP-1s: Why ResMed Stock Is a Bargain
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices. |
| 02 Nov 2026 | Yahoo Finance |
ResMed: 3 Key Takeaways for Long-Term Investors
Manufacturing gains are lifting margins faster than revenue growth, signaling operational leverage ahead. |
| 01 Nov 2026 | Yahoo Finance |
What Sent ResMed Stock Lower?
For questions about this article or underlying research, email [email protected]. |
| 31 Oct 2026 | Yahoo Finance |
RMD Q3 deep dive: product innovation and supply chain execution drive results amid evolving landscape
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q1 2027), with sales up 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates. |
| 30 Oct 2026 | Yahoo Finance |
ResMed (RMD) Looks Fully Valued After Another Earnings Beat
ResMed (RMD) just posted quarterly results that topped analyst expectations on both earnings and revenue, while reaffirming its full year outlook and highlighting firm demand for sleep devices, masks, and digital health tools. ResMed’s share price has climbed 13.5% over the past month and 19.8%… |
| 30 Oct 2026 | Yahoo Finance |
ResMed (RMD) Q1 2027 Earnings Call Transcript
Sleep device revenue grew 6% as AI tools boost therapy compliance and partnerships expand. |
| 30 Oct 2026 | Yahoo Finance |
ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
| 30 Oct 2026 | Yahoo Finance |
ResMed Inc. Q1 2027 Earnings Call Summary
Moby summary of ResMed Inc.'s Q1 2027 earnings call… |
| 30 Oct 2026 | Yahoo Finance |
What ResMed (RMD) Said on Its Q1 Earnings Call
ResMed (NYSE:RMD) reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in life-support device sales. Non-GAAP diluted earning… |
| 30 Oct 2026 | Yahoo Finance |
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth. |
| 29 Oct 2026 | Yahoo Finance |
ResMed (NYSE:RMD) posts better-than-expected sales in Q3 CY2026
Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in calendar Q3 2026 (fiscal Q1 2027), with revenue rising 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates. |
| 29 Oct 2026 | Yahoo Finance |
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
ResMed (RMD) delivered earnings and revenue surprises of +8.99% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 29 Oct 2026 | Yahoo Finance |
ResMed: Fiscal Q1 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal first-quarter net income of $418… |
| 29 Oct 2026 | Yahoo Finance |
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basisQ1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91Returned more than $1.0 billion to shareholders through share repurchases and dividends during Q1 Note: A webcast of Resmed’s… |
| 29 Oct 2026 | Yahoo Finance |
Ozlo Raises $22 Million Series B Led by Modi Ventures to Expand Its Sleep Technology Ecosystem
Funding will accelerate product development, sleep research, and new technologies addressing a broader range of sleep and nighttime health needs BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ozlo, the sleep technology company behind Ozlo Sleepbuds®, announced it has raised $22 million in Series B… |
| 28 Oct 2026 | Yahoo Finance |
Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026… |
| Show more | ||
| TTM Dividend Yield | 1.08% |
| 5Y Average Dividend Yield | 0.72% |
| Payout Ratio | 23.23% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 13 Feb 2025 | 30 Jan 2025 | 20 Mar 2025 | 0.53 Cash |
| 07 Nov 2024 | 24 Oct 2024 | 12 Dec 2024 | 0.53 Cash |
| 15 Aug 2024 | 01 Aug 2024 | 19 Sep 2024 | 0.53 Cash |
| 08 May 2024 | 25 Apr 2024 | 13 Jun 2024 | 0.48 Cash |
| 07 Feb 2024 | 24 Jan 2024 | 14 Mar 2024 | 0.48 Cash |
| 08 Nov 2023 | 26 Oct 2023 | 14 Dec 2023 | 0.48 Cash |
| 16 Aug 2023 | 03 Aug 2023 | 21 Sep 2023 | 0.48 Cash |
| 10 May 2023 | 27 Apr 2023 | 15 Jun 2023 | 0.44 Cash |
| 08 Feb 2023 | 26 Jan 2023 | 16 Mar 2023 | 0.44 Cash |
| 09 Nov 2022 | 27 Oct 2022 | 15 Dec 2022 | 0.44 Cash |
| 17 Aug 2022 | 11 Aug 2022 | 22 Sep 2022 | 0.44 Cash |
| 11 May 2022 | 28 Apr 2022 | 16 Jun 2022 | 0.42 Cash |
| 09 Feb 2022 | 27 Jan 2022 | 17 Mar 2022 | 0.42 Cash |
| 09 Nov 2021 | 28 Oct 2021 | 16 Dec 2021 | 0.42 Cash |
| 18 Aug 2021 | 05 Aug 2021 | 23 Sep 2021 | 0.42 Cash |
| 12 May 2021 | 29 Apr 2021 | 17 Jun 2021 | 0.39 Cash |
| 10 Feb 2021 | 28 Jan 2021 | 18 Mar 2021 | 0.39 Cash |
| 10 Nov 2020 | 29 Oct 2020 | 17 Dec 2020 | 0.39 Cash |
| 19 Aug 2020 | 05 Aug 2020 | 24 Sep 2020 | 0.39 Cash |
| 13 May 2020 | 30 Apr 2020 | 18 Jun 2020 | 0.39 Cash |
| 12 Feb 2020 | 30 Jan 2020 | 19 Mar 2020 | 0.39 Cash |
| 06 Nov 2019 | 25 Oct 2019 | 12 Dec 2019 | 0.39 Cash |
| 14 Aug 2019 | 26 Jul 2019 | 19 Sep 2019 | 0.39 Cash |
| 08 May 2019 | 03 May 2019 | 13 Jun 2019 | 0.37 Cash |
| 06 Feb 2019 | 25 Jan 2019 | 14 Mar 2019 | 0.37 Cash |
| 07 Nov 2018 | 26 Oct 2018 | 13 Dec 2018 | 0.37 Cash |
| 15 Aug 2018 | 03 Aug 2018 | 20 Sep 2018 | 0.37 Cash |
| 09 May 2018 | 26 Apr 2018 | 14 Jun 2018 | 0.35 Cash |
| 07 Feb 2018 | 23 Jan 2018 | 15 Mar 2018 | 0.35 Cash |
| 08 Nov 2017 | 26 Oct 2017 | 14 Dec 2017 | 0.35 Cash |
| 15 Aug 2017 | 01 Aug 2017 | 21 Sep 2017 | 0.35 Cash |
| 09 May 2017 | 27 Apr 2017 | 15 Jun 2017 | 0.33 Cash |
| 07 Feb 2017 | 23 Jan 2017 | 16 Mar 2017 | 0.33 Cash |
| 08 Nov 2016 | 25 Oct 2016 | 15 Dec 2016 | 0.33 Cash |
| 16 Aug 2016 | 28 Jul 2016 | 22 Sep 2016 | 0.33 Cash |
| 17 May 2016 | 26 Apr 2016 | 16 Jun 2016 | 0.3 Cash |
| 09 Feb 2016 | 21 Jan 2016 | 17 Mar 2016 | 0.3 Cash |
| 17 Nov 2015 | 22 Oct 2015 | 17 Dec 2015 | 0.3 Cash |
| 18 Aug 2015 | 30 Jul 2015 | 17 Sep 2015 | 0.3 Cash |
| 19 May 2015 | 23 Apr 2015 | 18 Jun 2015 | 0.28 Cash |
| 10 Feb 2015 | 22 Jan 2015 | 19 Mar 2015 | 0.28 Cash |
| 18 Nov 2014 | 23 Oct 2014 | 18 Dec 2014 | 0.28 Cash |
| 19 Aug 2014 | 31 Jul 2014 | 18 Sep 2014 | 0.28 Cash |
| 16 May 2014 | 23 Apr 2014 | 17 Jun 2014 | 0.25 Cash |
| 14 Feb 2014 | 23 Jan 2014 | 19 Mar 2014 | 0.25 Cash |
| 15 Nov 2013 | 24 Oct 2013 | 18 Dec 2013 | 0.25 Cash |
| 16 Aug 2013 | 01 Aug 2013 | 17 Sep 2013 | 0.25 Cash |
| 17 May 2013 | 25 Apr 2013 | 18 Jun 2013 | 0.17 Cash |
| 14 Feb 2013 | 24 Jan 2013 | 19 Mar 2013 | 0.17 Cash |
| 16 Nov 2012 | 25 Oct 2012 | 18 Dec 2012 | 0.17 Cash |
| 05 Sep 2012 | 02 Aug 2012 | 28 Sep 2012 | 0.17 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.530 | 1 | 0.22 |
| 2024 | 2.02 | 4 | 0.88 |
| 2023 | 1.84 | 4 | 1.07 |
| 2022 | 1.72 | 4 | 0.83 |
| 2021 | 1.62 | 4 | 0.62 |
| 2020 | 1.56 | 4 | 0.73 |
| 2019 | 1.52 | 4 | 0.98 |
| 2018 | 1.44 | 4 | 1.27 |
| 2017 | 1.36 | 4 | 1.61 |
| 2016 | 1.26 | 4 | 2.03 |
| 2015 | 1.16 | 4 | 2.16 |
| 2014 | 1.06 | 4 | 1.89 |
| 2013 | 0.840 | 4 | 1.78 |
| 2012 | 0.340 | 2 | 0.82 |
| Show more | |||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |